M. Özbalak Et Al. , "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience," ANNALS OF HEMATOLOGY , vol.99, no.2, pp.301-307, 2020
Özbalak, M. Et Al. 2020. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. ANNALS OF HEMATOLOGY , vol.99, no.2 , 301-307.
Özbalak, M., SALİHOĞLU, A., Soysal, T., Karadoğan, İ., PAYDAŞ, S., Özdemir, E., ... Yıldız, B.(2020). Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience. ANNALS OF HEMATOLOGY , vol.99, no.2, 301-307.
Özbalak, Murat Et Al. "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience," ANNALS OF HEMATOLOGY , vol.99, no.2, 301-307, 2020
Özbalak, Murat Et Al. "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience." ANNALS OF HEMATOLOGY , vol.99, no.2, pp.301-307, 2020
Özbalak, M. Et Al. (2020) . "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience." ANNALS OF HEMATOLOGY , vol.99, no.2, pp.301-307.
@article{article, author={Murat Özbalak Et Al. }, title={Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience}, journal={ANNALS OF HEMATOLOGY}, year=2020, pages={301-307} }